Blog @ Fordham IPLJ
Fordham Intellectual Property, Media & Entertainment Law Journal
November 18, 2024
In August of 2024, Former President Donald J. Trump shared numerous deepfake images of Taylor Swift endorsing his campaign for the 2024 presidential election. This high-profile example of artificial-intelligence-generated misinformation
November 16, 2024
Following the August 2024 arrest of Telegram founder Pavel Durov by France, Telegram announced new policies claiming to help authorities catch criminals who use the instant-messaging app. Some fear the
November 15, 2024
In February 2024, a jury agreed with Chanel that luxury reseller, What Goes Around Comes Around, misled consumers by promoting Chanel in its marketing materials. This win not only protects
November 14, 2024
While the FTC has adopted a new rule on the use of AI to inflate a business’s social media influence for commercial purposes, the FCC is considering a new rule
November 12, 2024
Viral social media trends collide with trademark law, revealing the rise of “trademark trolls” and legal implications of trademarking a slogan. The battle is between a TikTok influencer and a
November 11, 2024
Following his acquisition of Twitter, one of the largest used social media services, businessman Elon Musk sought to rebrand it to “X”, retiring the widely known bird logo entirely. This
November 8, 2024
In its recent decision in UMG Recordings, Inc. v. Grande Communications Networks, L.L.C., the Fifth Circuit has departed from its sister circuits with respect to the calculation of statutory damages
November 7, 2024
The Sports Broadcasting Act allows the NFL to sell all of its teams’ broadcasting rights collectively without violating antitrust laws. However, as there is a strong argument that this antitrust
November 5, 2024
Patent applications can run into a multitude of issues, including the Patent Office failing to meet statutorily guaranteed deadlines during its examinations. In this case, patent applicants have traditionally been
November 4, 2024
On Monday, October 7, 2024, Novo Nordisk Inc. and Viatris subsidiary Mylan Pharmaceuticals, Inc. came to a resolution in a patent lawsuit concerning the groundbreaking drug Ozempic, also known as
Loading new posts...
No more posts